News
-
September is Gynaecological Cancer Awareness Month and we're busting some myths
Help us bust some myths and make ovarian cancer a survivable disease
-
Ovarian Cancer Action becomes NCRI partner
Ovarian Cancer Action has joined the NCRI (National Cancer Research Institute) Partnership as a funder of cancer research. Ovarian Cancer Action joins 21 other funders of cancer research wishing to maximise the value and benefits of cancer research for patients and the public
-
"Cancer doesn't wait in line"
Ovarian Cancer Action is raising awareness of ovarian cancer in shopping malls around the UK, encouraging those experiencing symptoms to visit their GP and avoid late diagnosis.
-
New NHS data reveals England's ovarian cancer injustices
New NHS data shows that one in seven women diagnosed with ovarian cancer each year (13.6 per cent) die in the two months after diagnosis. The data is from the Ovarian Cancer Audit Feasibility Pilot jointly funded by us, the British Gynaecological Cancer Society and Target Ovarian Cancer. -
Ovarian Cancer Action turns “Tampon Tax” funds into innovative IMPROVE UK project
We have launched IMPROVE UK – an innovative project that aims to significantly reduce the unfairness women currently face in healthcare and the disproportionately low survival rates of women with ovarian cancer.
-
Avastin and Olaparib drug combination approved as treatment for women with advanced ovarian cancer
Today the National Institute for Health and Care Excellence (NICE) has announced a new maintenance treatment option for women with HRD positive advanced ovarian cancer in England. The new treatment is a welcome addition to a growing number of targeted therapy options that will help women with advanced ovarian cancer live longer.
-
Ovarian Cancer Action calls on the Government to invest in cancer and reduce patient inequalities
We are part of One Cancer Voice, a group of cancer charities who are calling on the Government to improve cancer care and survival by making a number of important funding commitments in their upcoming Spending Review.
-
New drug combination shows promise for ovarian cancer patients in early trial
A new combination of ovarian cancer drugs that shrinks low-grade serous ovarian cancer tumours has shown promising results in early clinical trials.
-
Protect the vulnerable as Covid-19 restrictions lift, urges cancer charities
From Monday 19th July, people are no longer required to wear face masks in crowded places or maintain social distance. While this will be a relief to many, it means that cancer patients - who are more at-risk from the virus and less protected by the vaccine than the general public - may feel they are once again unable to enjoy normal daily life and socialise safely.
-
WI members pass resolution to increase awareness of ovarian cancer symptoms
200,000 members of the Women’s Institute will mobilise and campaign for better awareness amongst those at risk of ovarian cancer and health professionals.
-
NHS England announces national ovarian cancer audit
NHS England have confirmed that the future of the ovarian cancer audit is secure, with the announcement that it is one of five new cancer audits to be commissioned by the Healthcare Quality Improvement Partnership (HQIP).
-
What is the national ovarian cancer audit?
With the UK’s ovarian cancer survival rates remaining some of the lowest in Europe, our Head of Public Affairs and Research looks at the game-changing announcement of a government-funded ovarian cancer audit, what this means for women with ovarian cancer, and how you helped us get there.
-
What has happened to the world's largest ovarian cancer screening trial?
Researchers at University College London have found that these screening approaches did not significantly reduce the chance of these women developing late stage ovarian cancer. Unfortunately, this means that these tests cannot be recommended as a screening programme for the public.
-
Women in Scotland gain new ovarian cancer treatment
The Scottish Medicine Consortium has made maintenance treatment Niraparib available to women diagnosed with advanced ovarian cancer in Scotland. -
It’s Ovarian Cancer Awareness Month and we’re putting the spotlight on age inequality
Over 7,000 women are diagnosed with ovarian cancer each year, with more than a third over the age of 70. Yet, in the first of a series of reports highlighting inequalities in ovarian cancer, women over 70 are not receiving the standard of care necessary to survive ovarian cancer.
-
Julia Bradbury is Ovarian Cancer Action's new charity ambassador
On 31st January Julia presented Ovarian Cancer Action’s BBC Lifeline Appeal. In her own words, Julia explains why she has chosen to support them in her new role as charity ambassador.
-
Ovarian Cancer Action's BBC Lifeline Appeal
Getting the nation's eyes on ovarian cancer. Julia Bradbury presents Ovarian Cancer Action's BBC Lifeline Appeal.
-
Niraparib - the latest treatment option for women with ovarian cancer in England
Today, women diagnosed with advanced ovarian cancer will have access to a life-extending drug called Niraparib, thanks to the National Institute for Health and Care Excellence (NICE).
-
New classification system “Oxford Classic” can create accurate predictions of ovarian cancer outcomes
Ovarian Cancer Action funded researcher, Professor Ahmed Ahmed, from the University of Oxford Weatherall Institute, is already making several exciting breakthroughs with his research - in more areas than one.
-
The BioIndustry Association announces 2021 charity partnership with Ovarian Cancer Action
Ovarian Cancer Action is proud to announce that it is the BioIndustry Association’s (BIA) chosen charity partner for 2021.